文献速递治疗药物监测与药物基因组学特殊人群用药

高剂量利福平模型引导精准给药:坦桑尼亚与南非结核患者简约群体药代动力学模型

Towards Model-Informed Precision Dosing of High-Dose Rifampicin: A Parsimonious Population Pharmacokinetic Model Capturing Saturation and Autoinduction in Tanzanian and South African Patients with Tuberculosis.
PubMed 文献 · Clin Pharmacokinet · 2026-09-15

本研究基于42例坦桑尼亚和92例南非结核患者(剂量达50 mg/kg,历时2周)的利福平浓度数据,构建了一个包含米氏消除和时间依赖性Emax自身诱导的简约一室群体药代动力学模型。该模型个体贝叶斯预测性能与两个复杂参考模型相当,并证实相同体重剂量队列内暴露差异可达五倍,支持采用模型引导精准给药和治疗药物监测替代统一按体重给药。

要点

  • 简约一室模型联合米氏消除与Emax自身诱导可充分描述利福平药代动力学。
  • 相同体重剂量下个体间暴露差异可达五倍,支持个体化给药。
  • 模型预测性能与复杂参考模型相当,可作为临床决策支持工具基础。

核心结论

  • 简约群体药代动力学模型成功捕捉利福平的饱和消除与自身诱导特征,预测性能与复杂参考模型相当。
  • 相同体重剂量队列内利福平暴露差异可达五倍,支持采用模型引导精准给药和治疗药物监测。

研究设计与样本

  • 研究纳入42例坦桑尼亚和92例南非结核患者,利福平剂量达50 mg/kg,历时2周。
  • 基于上述浓度数据开发简约群体药代动力学模型,并与文献参考模型进行基准比较。

主要发现

  • 最终模型采用一室结构、米氏消除和时间依赖性Emax自身诱导函数。
  • 最终模型个体贝叶斯预测性能与两个复杂参考群体药代动力学模型相当。
  • 相同体重给药队列内利福平暴露差异可达五倍。

关键数值与推荐

  • 模型结构为一室模型联合米氏消除与时间依赖性Emax自身诱导函数。
  • 剂量覆盖达50 mg/kg,疗程2周。

临床怎么用

  • 临床可基于该模型实施模型引导精准给药和治疗药物监测,替代统一按体重给药以提升疗效与安全性。
  • 该模型可作为高结核负担地区个体化给药和临床决策支持工具部署的稳健基础。

局限性

  • 现有群体药代动力学模型较少纳入坦桑尼亚患者且简约模型不多,本研究模型仍需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rifampicin, a cornerstone of tuberculosis treatment, exhibits complex pharmacokinetics with variable absorption, saturable elimination and time-dependent autoinduction, together with marked inter- and intra-individual variability in drug exposure. These properties challenge standard weight-based dosing and underscore the need for individualized strategies, particularly in high-burden settings like Tanzania. While therapeutic drug monitoring (TDM) supported by model-informed precision dosing (MIPD) is being implemented, few of the existing population pharmacokinetic (popPK) models includes Tanzanians and are parsimonious. OBJECTIVE: This study aimed to develop a parsimonious popPK model of rifampicin that successfully captures both its autoinductive and saturable elimination components, achieving predictive performance comparable to more complex reference models described in the literature. METHODS: Rifampicin concentrations data from 42 Tanzanian and 92 South African patients, covering doses up to 50 mg/kg over 2 weeks were used to develop the model, which was further benchmarked against literature reference models. RESULTS: The chosen model employed a one-compartment structure with Michaelis-Menten elimination and a time-dependant Emax-based autoinduction function. The final model demonstrated individual Bayesian predictive performance comparable to two complex reference popPK models, and confirmed substantial inter-individual variability in exposure, with exposures differing by up to fivefold within the same weight-based dosing cohort. CONCLUSION: These findings support the implementation of MIPD and TDM to improve efficacy and safety in TB treatment rather than relying on a uniform dosing approach based on bodyweight. This model provides a robust foundation for individualized dosing and the deployment of clinical decision support tools in high TB burden settings.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Petermann YJ, Said B, Sariko ML, et al. Towards Model-Informed Precision Dosing of High-Dose Rifampicin: A Parsimonious Population Pharmacokinetic Model Capturing Saturation and Autoinduction in Tanzanian and South African Patients with Tuberculosis. Clin Pharmacokinet. 2026. PMID: 42744994. doi:10.1007/s40262-026-01674-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。